Agfa-Gevaert
Mortsel, Belgium – March 10, 2021 – 7:45 a.m. CET
The Agfa-Gevaert Group today announced a share buyback program with a volume of up to 50 million Euro.
The program was decided by the Board of Directors on March 9, 2021. Under this program, which will start on April 1, 2021 and has a planned duration of maximum 12 months, the Agfa-Gevaert Group may acquire its common stock, for a maximum consideration of 50 million Euro. The Board also approved the cancellation of the 4,099,852 treasury shares currently held by the company.
The share repurchases will be conducted under the terms and conditions approved by the Extraordinary General Meeting of Shareholders of the Group of May 12, 2020. The program will be implemented in accordance with industry best practices and in compliance with the applicable buyback rules and regulations. To this end, an independent financial intermediary will repurchase shares on the basis of a discretionary mandate. During the program, the Group will regularly publish press releases with updates on the progress made (if any), as required by law. This information will also be available on the investor relations pages of the Group’s website.
The purpose of the program is to reduce the issued capital of the Group and to cancel all or part of the purchased shares.
"This share buyback program allows our shareholders to benefit from the sale of part of our HealthCare IT activities, which was concluded in May 2020. Furthermore, it shows our confidence in our ongoing transformation process. We are on the right track to execute the growth strategies we have drawn up for our divisions and to create future shareholder value," said Pascal Juéry, President and CEO of the Agfa-Gevaert Group.
About Agfa
The Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions, HealthCare IT, Digital Print & Chemicals and Offset Solutions. They develop, manufacture and market analogue and digital systems for the healthcare sector, for specific industrial applications and for the printing industry. In 2020, the Group realized a turnover of 1,709 million Euro.
Contact:
Viviane Dictus
Director Corporate Communication
T +32 (0) 3 444 71 24
E viviane.dictus@agfa.com
Johan Jacobs
Corporate Press Relations Manager
T +32 (0)3/444 80 15
E johan.jacobs@agfa.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zealand Pharma18.7.2025 18:30:00 CEST | Press release
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
SpringWorks Therapeutics, Inc.18.7.2025 17:30:40 CEST | Press release
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Photocat A/S18.7.2025 17:00:00 CEST | Press release
PHOTOCAT has today applied for a transfer of its trading venue from Nasdaq First North Growth Market to Spotlight Stock Market.
Golden Ocean Group Limited18.7.2025 16:30:00 CEST | Press release
GOGL – Notice of Special General Meeting
Kapitalforeningen SDG Invest18.7.2025 16:06:31 CEST | Pressemeddelelse
Kapitalforeningen SDG Invest - Opdateret prospekt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom